doses studied // research context
CJC-1295 Ipamorelin Dosage: The Research Numbers, Not a Protocol
What was given, to which species, by which route — and the half-lives that make the two halves mismatch. No human dosing.
Read this first
This page reports CJC-1295 Ipamorelin dosage the way the studies report it — as research data, not a recipe. No human protocol appears here, no "take this much," no schedule to follow. What you will find: the doses given to people and animals in published work, the routes used, and the half-lives — because the half-lives are the whole story of why this pairing is awkward to dose. CJC-1295 with DAC lingers for days; ipamorelin is gone in hours; the no-DAC CJC-1295 (Mod GRF 1-29) is gone in about half an hour. Pairing a slow agent with a fast one means the net growth-hormone exposure for any specific routine has never been characterized. Doses below are written only as "studied at X in [species] by [route]."
Cjc 1295 ipamorelin dosage
What the literature recorded, by component:
CJC-1295 (with DAC). Studied at 30–90 µg/kg subcutaneous in human Phase 1 pharmacokinetic work [1]; modelled at 2 µg/day in GHRH-knockout mouse studies. The single human dose of 30 or 60 µg/kg is the one that produced the 2- to 10-fold GH and 1.5- to 3-fold IGF-1 elevations [1].
CJC-1295 no-DAC (Mod GRF 1-29). A short, pulsatile GHRH signal; no formal standalone human PK study exists, and research protocols model it at roughly 100–200 µg per injection.
Ipamorelin. Rodent dosing recorded at 100 µg/kg three times daily (bone studies), 0.5 mg/kg/day (bone mineral), 0.01–1 mg/kg IV (GI motility); about 1 µg/kg plateaued the GH response in rodent models. Swine ED50 was 2.3 nmol/kg [2]. No validated human PK for ipamorelin is published.
Note what is absent: there is no studied dose for the combination. These are single-component research numbers, reported for documentation, not for use.
Half-life: why the two halves mismatch
Half-life (the time for half a dose to clear) is where this pairing gets interesting — and is exactly the cjc 1295 dac vs mod grf 1-29 distinction.
- CJC-1295 with DAC: about
6–8 daysin humans, because the DAC moiety covalently binds albumin and rides it; albumin-bound peptide was detectable in rat plasma beyond 72 hours [5][1]. - CJC-1295 no-DAC (Mod GRF 1-29): on the order of
minutes to ~30 min, like native GHRH(1-29), because DPP-IV (a serum enzyme) cleaves it quickly. - Ipamorelin: under about
2 hoursin rodent plasma, with peak GH response around 40 minutes post-dose; no validated human half-life is published.
The mismatch is structural: a multi-day GHRH background under a short, hours-long GHRP pulse. The synergy literature studied short pulses of both [3]; chronic continuous GHRH drive from the DAC form is a different exposure profile entirely [1].
Routes, handling, and stability
Routes studied: subcutaneous and intravenous, plus continuous subcutaneous infusion (osmotic minipump, rodent models) and intranasal (ipamorelin rodent PK).
Handling, in standard laboratory context only: lyophilised (freeze-dried) peptide is stable frozen for extended periods. After reconstitution with bacteriostatic water (sterile water with 0.9% benzyl alcohol as preservative), aqueous peptide solutions are kept refrigerated at 2–8 °C and degrade over weeks via asparagine deamidation — and degradation products can be markedly less potent. Avoid agitation and repeated freeze-thaw. GHRH analogues undergo DPP-IV cleavage in plasma; CJC-1295's amino-acid substitutions and its DAC were engineered to resist it [5]. None of this is administration guidance — it is the stability profile recorded in the handling literature.
What the human record actually contains
CJC-1295 (DAC) reached Phase 2 development, which was discontinued — a Phase 2 program ended after an adverse event in one subject, reported as unrelated to the established mechanism. Phase 1 data in healthy adults characterised the pharmacokinetics and dose-response [1]. Ipamorelin was investigated, including a postoperative-ileus program, but was not advanced to approval; its class rationale there rests on related ghrelin-receptor agonists improving GI transit in rat models [11][12].
The bottom line for dosing: there is no peer-reviewed human pharmacology study of the pre-mixed CJC-1295/ipamorelin combination. Any combination dose is unstudied. This page documents the single-component research record and stops there.